IRVINE, Calif. -- (Business Wire)
Khang & Khang LLP (the “Firm”) announces that it is investigating claims
against Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (Nasdaq:
AGIO) concerning possible violations of federal securities laws.
If you purchased shares of Agios Pharmaceuticals, Inc. and want more
information free of charge, please contact Joon M. Khang, Esquire, of
Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by
telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
During the 2016 American Society of Hematology meeting, Agios presented
new information for its AG-348 and AG-519 molecules, which are used to
treat pyruvate kinase deficiency. Agios mentioned that a case of Grade 2
thrombocytopenia, which reduces platelets in blood cells, was found in a
patient receiving AG-519 and that after a dose of 300 mg, a negative
event of drug-related cholestatic hepatitis was found in a
bioavailability and food effect study. Following this release, Agios
stock dropped, causing investors harm.
If you have any questions concerning this notice or your rights, please
contact Joon M. Khang, a prominent litigator for almost two decades, by
telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161208006388/en/
Contacts:
Khang & Khang LLP
Joon M. Khang, Esq.
Telephone:
949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com
Source: Khang & Khang LLP
© 2024 Canjex Publishing Ltd. All rights reserved.